Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis

Clinical Therapeutics

Volumn 18, Issue 4, 1996, Pages 578-590

  Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GRANISETRON; METHOTREXATE; METOCLOPRAMIDE; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; VINCRISTINE; ONDANSETRON; SEROTONIN ANTAGONIST;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; ORAL DRUG ADMINISTRATION; VOMITING; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; REVIEW;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; GRANISETRON; HUMANS; INJECTIONS, INTRAVENOUS; METOCLOPRAMIDE; NAUSEA; ONDANSETRON; SEROTONIN ANTAGONISTS;

EID: 0029746647     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/s0149-2918(96)80209-8     Document Type: Editorial

References (38)

1. Grunberg SM. Potential for combination therapy with the new antiserotonergic agents. Eur J Cancer. 1993;29A(Suppl 1):S39-S41.
2. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. NEJM. 1981;305:905-909.
3. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986;88:497-499.
4. Merrifield KR, Chafee BJ. Recent advances in the management of nausea and vomiting caused by antineoplastic agents. Clin Pharm. 1989;8:187-199.
5. 3 receptor antagonists as anti-emetics. Trends Pharmacol Sci. 1991;12:46-48.
6. Smyth JF. New directions for anti-emetic research. Ann Oncol. 1994;5:569-570.
7. Soukop M, McQuade B, Hunter E, et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology (Switzerland). 1992;49:295-304.
8. Roila F, Tonato M, Basurto C, et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: A randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1987;5:141-149.
9. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: A review. Ann Oncol. 1991;2:107-114.
10. Bleiberg HH, Spielmann M, Falkson G, Romain D. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: A dose-ranging study. Clin Ther. 1995;17:38-51.
11. Hesketh P, Burris H, Cohn J, et al. A double-blind comparison of the efficacy and safety of oral granisetron with oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Cancer J. In press.
12. Ettinger D, Eisenberg P, Fitts D, et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer. 1996;78:144-151.
13. Heron JF, Goedhals L, Jordaan JP, et al. Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol. 1994;5:579-584.
14. Hacking A, on behalf of the Granisetron Study Group. Oral granisetron - simple and effective: A preliminary report. Eur J Cancer. 1992;28A(Suppl 1):S28-S32.
15. Johnsonbaugh RE, Mason BA, Friedman CJ, Fitts D. Oral granisetron is an effective anti-emetic in patients receiving moderately emetogenic chemotherapy. Proc Am Soc Clin Oncol. 1994;13:437. Abstract.
16. Aapro MS. Controlling emesis related to cancer therapy. Eur J Cancer. 1991;27: 356-361.
17. Seynaeve C, De Mulder PHM, Verweij J, Gralla RJ. Controlling cancer chemotherapy-induced emesis. Pharm Weekbl Sci. 1991;13:189-197.
18. Smith DB, Newlands ES, Rustin GJS, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet. 1991; 338:487-490.
19. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24 hours following high dose cisplatin chemotherapy. Proc Am Soc Clin Oncol. 1993;12:133. Abstract.
20. Carmichael J, Bessell E, Harris AL, et al. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br J Cancer. 1994;70:1161-1164.
21. Marr HE, Davey PT, Boyle EA, Blower PR. Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret. Pharmacology. 1994;48: 283-292.
22. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer. 1990;26(Suppl 1):S23-S27.
23. Chevallier B, on behalf of the Granisetron Study Group. The control of acute cisplatin-induced emesis - a comparative study of granisetron and a combination regimen of metoclopramide and dexamethasone. Br J Cancer. 1993;68:176-180.
24. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a highly selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994;12:2204-2210.
25. Riviere A, on behalf of the Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer. 1994;69:967-971.
26. Soukop M, on behalf of the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer. 1994;2:177-183.
27. Cooke CE, Mehra IV. Oral ondansetron for preventing nausea and vomiting. Am J Hosp Pharm. 1994;51:762-771.
28. 3-Antagonisten Ondansetron. Onkologie. 1990;13:313-315.
29. Campora E, Oliva C, Mammoliti S, et al. Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. Breast Cancer Res Treat. 1991;19: 129-132.
30. Rosso R, Campora E, Cetto G. et al. Oral ondansetron (GR 38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Anticancer Res. 1991; 11: 937-940.
31. Beck TM, Ciociola AA, Jones SE, et al. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med. 1993;118:407-413.
32. 3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Am J Clin Oncol Cancer Clin Trials. 1994;17:137-146.
33. Herrstedt J, Sigsgaard T, Boesgaard M, et al. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. NEJM. 1993;328:1076-1080.
34. Fraschini G, Ciociolo A, Esparza L, et al. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol. 1991;9:1268-1274.
35. Marschner NW, Adler M, Nagel GA, et al. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer. 1991;27:1137-1140.
36. Levitt M, Warr D, Yelle L, et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate and fluorouracil. NEJM. 1993;328:1081-1084.
37. Yarker YIE, McTavish D, Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs. 1994;48:761-793.
38. De Bruijn KH, Tropisetron: A review of clinical experience. Drugs. 1992;43(Suppl 3):11-22.